Table 1 Summary of the clinical data of lung cancer patients for PDX models
# | Number | Age | Sex | Pattern of organization | Tumor differentiation | TNM Staging | Lymph Node Metastasis | Engrafted model | Primary cell lines | EGFR mutation |
|---|---|---|---|---|---|---|---|---|---|---|
1 | LG1 | 45 | Female | Adenocarcinoma | Poor | T2bN0M0 | Y | Y | Y | L858R |
2 | LG2 | 69 | Female | Adenocarcinoma | Moderate | T1aN0M0 | N | Y | N | Exon19 delete |
3 | LG3 | 74 | Male | Adenocarcinoma | Moderately-poor | T1bN0M0 | N | Y | N | Wild type |
4 | LG6 | 60 | Male | Squamous carcinoma | Moderately-poor | T2aN0M0 | N | Y | Y | Wild type |
5 | LG7 | 43 | Male | Mucoepidermoid carcinoma | Moderately-poor | T2bN0M0 | Y | Y | Y | Wild type |
6 | LG10 | 62 | Female | Adenocarcinoma | Moderate | T1N0M0 | N | N | N | Wild type |
7 | LG12 | 75 | Male | Squamous carcinoma | Moderately-poor | T2bN0M0 | N | Y | Y | Wild type |
8 | LG14 | 77 | Male | NE and SCLC | Well | T2N1M0 | Y | Y | N | Wild type |
9 | LG17 | 72 | Male | Adenocarcinoma | Moderately-good | T2N0M0 | N | Y | N | Wild type |
10 | LG19 | 53 | Male | Squamous carcinoma | Moderate | T1N0M0 | N | N | Y | Wild type |
11 | LG21 | 67 | Male | Adenocarcinoma | Moderate | T2N0M0 | N | N | N | Wild type |
12 | LG22 | 55 | Male | Squamous carcinoma | Moderate | T2aN0M0 | N | Y | N | L858R |
13 | LG24 | 40 | Male | SCLC | Moderately-poor | T2N0M0 | N | Y | N | Wild type |
14 | LG26 | 50 | Male | Squamous carcinoma | Moderately-poor | T2bN0M0 | N | Y | N | Wild type K-RAS |
15 | LG28 | 60 | Male | Squamous carcinoma | Moderate | T2bN1M0 | Y | Y | N | colon12 GGT > CGT |
16 | LG29 | 58 | Male | Squamous carcinoma | Moderately-good | T2bN0M0 | N | Y | N | Wild type |
17 | LG33 | 58 | Male | Squamous carcinoma | Moderate | T3N1M0 | N | Y | N | Wild type |
18 | LG37 | 64 | Male | Squamous carcinoma | Poor | T4N1M0 | Y | Y | Y | Wild type |
19 | LG38 | 46 | Male | Squamous carcinoma | Moderately-good | T2N0M0 | N | Y | N | Wild type |
20 | LG42 | 67 | Male | Squamous carcinoma | Moderately-good | T2N1M0 | Y | N | N | Wild type |
21 | LG44 | 58 | Male | NSCLC | Poor | T2aN0M0 | N | Y | N | Wild type |
22 | LG46 | 56 | Female | Squamous carcinoma | Poor | T2aN1M0 | Y | Y | N | Wild type |
23 | LG48 | 50 | Male | Adenocarcinoma | Moderate | T2N1M0 | Y | N | Y | Wild type |
24 | LG50 | 75 | Female | Adenocarcinoma | Moderate | T2N0M0 | N | Y | Y | Wild type |
25 | LG52 | 56 | Male | Squamous carcinoma | Moderate | T1N1M0 | Y | N | N | Wild type |
26 | LG53 | 65 | Male | Adenosquamous carcinoma | Poor | T2aN1M0 | Y | Y | N | Wild type |
27 | LG54 | 70 | Male | Adenocarcinoma | Moderate | T1N0M0 | N | N | N | Wild type |
28 | LG55 | 64 | Male | Adenocarcinoma | Moderate | T2aN0M0 | N | N | Y | Wild type |
29 | LG59 | 68 | Male | Squamous carcinoma | Well | T1N0M0 | N | N | N | Wild type |
30 | LG61 | 59 | Male | Squamous carcinoma | Moderately-poor | T2N2M0 | Y | Y | Y | Wild type |
31 | LG62 | 67 | Male | Adenocarcinoma | Poor | T2bN0M0 | N | N | N | Wild type |